Osteosarcoma News and Research

RSS
Between two and three percent of all childhood cancers are osteosarcoma. Because osteosarcoma usually develops from osteoblasts, it most commonly affects children and young adults experiencing their adolescent growth spurt. Boys and girls have a similar incidence rate until later in their adolescence, when boys are more commonly affected. While most tumors occur in larger bones, such as the femur, tibia, and humerus, and in the area of the bone that has the fastest growth rate, they can occur in any bone. The most common symptom is pain, but swelling and limited movement can occur as the tumor grows.

Osteosarcoma is an orphan disease with approximately 1,200 new cases diagnosed in the United States each year. A similar incidence of the disease exists in Europe. According to the Children's Oncology Group (COG), the survival of children with osteosarcoma has remained at 60-65 percent since the mid-1980s. The standard treatment for osteosarcoma is tumor resection with combination chemotherapy before and after surgery.
Adolescents and young adults have lower cancer survival rates compared to children

Adolescents and young adults have lower cancer survival rates compared to children

Scientists develop new technology that helps visualize translation of mRNA into proteins

Scientists develop new technology that helps visualize translation of mRNA into proteins

New TAU study suggests potential therapeutic pathway to keep osteosarcoma lesions dormant

New TAU study suggests potential therapeutic pathway to keep osteosarcoma lesions dormant

DNA imprinting defect may affect children diagnosed with osteosarcoma

DNA imprinting defect may affect children diagnosed with osteosarcoma

Bayer to present new research findings on Xofigo (radium Ra 223 dichloride) injection at ASCO GU 2016

Bayer to present new research findings on Xofigo (radium Ra 223 dichloride) injection at ASCO GU 2016

Scientists discover that blocking RANKL protein stops osteosarcoma

Scientists discover that blocking RANKL protein stops osteosarcoma

Mylan announces U.S. launch of generic Fusilev for Injection

Mylan announces U.S. launch of generic Fusilev for Injection

CNIO researchers identify molecular mechanisms that determine cancer predisposition in DBA patients

CNIO researchers identify molecular mechanisms that determine cancer predisposition in DBA patients

Dan's House of Hope selected to receive ASTRO's 2015 Survivor Circle grant

Dan's House of Hope selected to receive ASTRO's 2015 Survivor Circle grant

CTCA at Western begins clinical trial that combines immunotherapy with chemotherapy to target sarcomas

CTCA at Western begins clinical trial that combines immunotherapy with chemotherapy to target sarcomas

Cancer-causing gene disrupts internal rhythm, metabolic pathways in cancer cells

Cancer-causing gene disrupts internal rhythm, metabolic pathways in cancer cells

CHAM, AECC receive $1.3 million NCI grant to advance more effective bone cancer treatments for children

CHAM, AECC receive $1.3 million NCI grant to advance more effective bone cancer treatments for children

UofL conducts Phase I research study for children with relapsed tumors

UofL conducts Phase I research study for children with relapsed tumors

Study uncovers complicated role of simple protein in spread of osteosarcoma

Study uncovers complicated role of simple protein in spread of osteosarcoma

Fennec presents positive interim results from phase III trial of sodium thiosulphate at ASCO 2015

Fennec presents positive interim results from phase III trial of sodium thiosulphate at ASCO 2015

FDA clears ADXS-HPV plus epacadostat IND for HPV-associated cervical cancer Phase 2 study

FDA clears ADXS-HPV plus epacadostat IND for HPV-associated cervical cancer Phase 2 study

New genetic models allow for comprehensive analysis of drivers for osteosarcoma

New genetic models allow for comprehensive analysis of drivers for osteosarcoma

Stem cell disease model reveals how tumor suppressor may drive bone cancer

Stem cell disease model reveals how tumor suppressor may drive bone cancer

Researchers pinpoint molecular mechanisms that inhibit Hippo pathway in pediatric bone cancers

Researchers pinpoint molecular mechanisms that inhibit Hippo pathway in pediatric bone cancers

Shire announces availability of Natpara (parathyroid hormone) for injection in U.S.

Shire announces availability of Natpara (parathyroid hormone) for injection in U.S.